June 1, 2012
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Tibet Pharmaceuticals, Inc. ("Tibet Pharmaceuticals" or the "Company") (OTC: TBET).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that Tibet Pharmaceuticals misrepresented and failed to disclose material internal control deficiencies, which rendered the Company's registration statement and prospectus to be materially false and misleading. These problems ultimately caused NASDAQ to halt and delist the Company's stock.
Request more information now by clicking here:
If you purchased Tibet Pharmaceutical securities after
December 28, 2010
and would like to discuss your legal rights, visit
. You can also contact us by calling
toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to
Faruqi & Faruqi, LLP also encourages anyone with information regarding Tibet Pharmaceutical's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (
). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential matter.
FARUQI & FARUQI, LLP369 Lexington Avenue, 10th Floor
New York, NY
Juan E. Monteverde, Esq.
Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP